8-K

$ABT · Abbott Laboratories

October 21, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Abbott Laboratories filed a current report on Form 8-K dated October 21, 2026, announcing its results of operations for the third quarter of 2026. The filing states that Abbott issued a news release with those results, and that release is included as Exhibit 99.1 to the report.

In the news release, Abbott presents various non-GAAP financial measures, including net earnings excluding specified items. The company explains that these measures adjust for factors it considers unusual or unpredictable, such as acquisition-related expenses, legal settlements, stock-based compensation, restructuring actions, certain regulatory costs, tax items, and intangible amortization expense. Abbott states that management believes these measures provide useful information for evaluating ongoing business performance, while cautioning that they should be considered in addition to, not as a substitute for, GAAP financial measures.

The 8-K was signed by Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer. The report also includes the cover page interactive data file as Exhibit 104.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →